Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1462 Results for "
intrapulmonary replication
" in MedChemExpress (MCE) Product Catalog:
Products (1462)
1462 Results for "intrapulmonary replication" in MCE Product Catalog:
Cat. No.: HY-128854S
CAS No.: 1219803-50-5
Cat. No.: HY-179433
Research Areas:
PROTAC AR Degrader-12 is a highly efficient PROTAC targeting AR coactivator binding site (AR-CBS). PROTAC AR Degrader-12 induces AR degradation in a ubiquitin proteasome system (UPS) pathway-dependent manner. PROTAC AR Degrader-12 inhibits tumor cell growth by affecting DNA replication and cell division PROTAC AR Degrader-12 could not only effectively degrade AR, but also potently inhibit the proliferation of MCF-7 and multiple mutant or resistant BC cells. PROTAC AR Degrader-12 effectively blocked estrogen receptor α (ERα) signaling through a dual mechanism involving ERα protein downregulation and suppression of its transcriptional activity. PROTAC AR Degrader-12 significantly inhibits the mRNA expression of FOXA1, GREB1, SRC, and PELP1. PROTAC AR Degrader-12 can be used for the study of breast cancer .
Cat. No.: HY-179556
SARS-CoV-2 nsp14-IN-10 is a highly potent and selective NSP14 (IC50 = 0.34 µM) S-adenosylmethionine (SAM) binding pocket inhibitor. SARS-CoV-2 nsp14-IN-10 demonstrates robust antiviral activity against SARS-CoV-2. SARS-CoV-2 nsp14-IN-10 exhibits broad-spectrum activity against other betacoronaviruses and inhibits SARS-CoV-2 at the replication stage. SARS-CoV-2 nsp14-IN-10 suppresses viral translation and exhibits immunostimulatory effects. SARS-CoV-2 nsp14-IN-10 specifically reverses NSP14-mediated alterations inhost transcriptome. SARS-CoV-2 nsp14-IN-10 can be used for the study of SARS-CoV-2 .
Cat. No.: HY-180269
Target:
Research Areas:
Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection .
Cat. No.: HY-189662
Target:
Research Areas:
Y-U0-S is a potent inhibitor of the coronavirus main protease (M pro) and host cathepsins. The IC50 values of Y-U0-S against SARS-CoV-2 M pro, SARS-CoV Mpro, Cathepsin B, and Cathepsin L are 0.81, 1.14, 0.86, and 21.13 μM, respectively. Y-U0-S exhibits broad-spectrum anti-coronavirus activity, with an EC50 of 0.22 μM against wild-type SARS-CoV-2. Y-U0-S forms an irreversible covalent bond with the catalytic site C145 of M pro through its aldehyde warhead, and by optimizing multi-site occupancy of the scaffold to engage conserved residues, it effectively blocks enzyme activity and inhibits viral replication. Y-U0-S can be used for research on COVID-19 .
Cat. No.: HY-N0168A
CAS No.: 69097-99-0
Target:
Cat. No.: HY-W105601R
CAS No.: 161599-46-8
Synonyms: 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine (Standard)
Research Areas:
5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (Standard) is the analytical standard of 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine. This product is intended for research and analytical applications. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine) is an antiviral compound that inhibits HBV reverse transcriptase activity. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine shows potential to control HBV replication in vitro. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine, as a nucleoside analog, may provide a new option for the suppression of chronic hepatitis B .
Cat. No.: HY-113308AR
CAS No.: 6042-32-6
Cat. No.: HY-128866
CAS No.: 2332841-25-3
TBAJ-876 is an orally active diarylquinoline anti-Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis, and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus, reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics. TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases .
Cat. No.: HY-13323R
CAS No.: 1138549-36-6
Target:
Reference Standards DNA/RNA Synthesis MDM-2/p53 AMPK Akt Autophagy Apoptosis Checkpoint Kinase (Chk)
Research Areas:
CX-5461 (Standard) is the analytical standard of CX-5461 (HY-13323). This product is intended for research and analytical applications. CX-5461 is a selective, orally active RNA polymerase I inhibitor. CX-5461 disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors .
Cat. No.: HY-15136B
CAS No.: 193275-86-4
Synonyms: Sch66336 racemate
Target:
Farnesyl Transferase Tau Protein RSV Akt Ras Bcl-2 Family STAT nAChR Apoptosis Autophagy Drug Isomer
Research Areas:
(Rac)-Lonafarnib (Sch66336 racemate) is an isomer of Lonafarnib (HY-15136). Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria .
Cat. No.: HY-164702
Synonyms: Izalontamab Brengitecan
Research Areas:
BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research .
Cat. No.: HY-189210A
Target:
Research Areas:
TopBP1-IN-4 is a TopBP1 inhibitor, with an IC50 value of 2.47 to 3.8 nM against the TopBP1 BRCT7/8 domain. TopBP1-IN-4 selectively disrupts BRCT7/8-dependent oncogenic protein-protein interactions, does not interfere with other BRCT domain-mediated functions of TopBP1, and has no effect on DNA replication. TopBP1-IN-4 restores E2F1-mediated Apoptosis in cells. TopBP1-IN-4 induces mitotic catastrophe in cells. TopBP1-IN-4 overcomes Osimertinib (HY-15772) resistance in EGFR-mutant non-small cell lung cancer models. TopBP1-IN-4 can be used in studies related to triple-negative breast cancer, ovarian cancer, non-small cell lung cancer, and acute myeloid leukemia .
Cat. No.: HY-189635
Target:
Research Areas:
NS3-IN-2 is a dual-target inhibitor targeting both NS2B‑NS3pro and NS3hel of West Nile virus (WNV). NS3-IN-2 inhibits the enzymatic activity of NS2B‑NS3pro toward polypeptide substrates in a non-competitive manner; for NS3hel, the compound exhibits a non-competitive inhibition mode with respect to ATP and competitive inhibition with respect to the dsDNA substrate. In biochemical assays, NS3-IN-2 has an IC50 = 4.4 μM against NS2B‑NS3pro and an IC50 = 24.0 μM against NS3hel helicase activity. NS3-IN-2 reduces WNV viral replication and exhibits cytotoxicity in hepatoma cells. NS3-IN-2 can be used for research on West Nile virus infection .
Cat. No.: HY-N0168AR
CAS No.: 69097-99-0
Target:
Cat. No.: HY-N0168AS
CAS No.: 1346605-26-2
Cat. No.: HY-P5522
CAS No.: 877462-71-0
Synonyms: L-Ala-γ-D-Glu-meso-diaminopimelic acid
Research Areas:
Cat. No.: HY-W015815R
CAS No.: 6960-22-1
Category:
Cat. No.: HY-L027
1,237 compounds
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.
MCE designs a unique collection of 1,237 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
